SOUL is a large randomized trial of oral semaglutide in adults with type 2 diabetes and established cardiovascular or kidney disease. In this Hormone Insight clinical evidence discussion, we cover the five-part PICO, the primary MACE result, absolute event rates, the non-significant kidney secondary outcome, patient selection, and limits of generalization. Fahad narration, clean voice-only production, no music. Primary source: PMID 40162642. DOI 10.1056/NEJMoa2501006. For healthcare professionals. This episode is an evidence discussion, not a substitute for the original paper, product information, local guidance, or individualized clinical judgment.

Can once-weekly semaglutide produce meaningful weight loss in adults with obesity?

In this 2-minute evidence brief, we break down the STEP 1 trial, a randomized double-blind clinical trial published in the New England Journal of Medicine in 2021. The study tested semaglutide 2.4 mg once weekly versus placebo, both with lifestyle intervention, in adults with overweight or obesity but without diabetes.

Covered in this video:

• Why the STEP 1 trial was done
• How the trial was conducted
• Main weight loss results
• Safety and gastrointestinal side effects
• Key clinical takeaway
• 
  

Main result: average body weight decreased by 14.9% with semaglutide versus 2.4% with placebo over 68 weeks.

Citation:

Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.

PMID: 33567185

DOI: 10.1056/NEJMoa2032183

This video is for medical education only and does not replace clinical judgment or individual medical advice.

#Semaglutide #STEP1Trial #ObesityMedicine #GLP1 #MedicalEducation

semaglutide, STEP 1 trial, semaglutide obesity, semaglutide weight loss, Wegovy, GLP-1 receptor agonist, obesity treatment, obesity medicine, clinical trial explained, randomized controlled trial, RCT, NEJM, weight loss medication, semaglutide 2.4 mg, evidence based medicine, medical education, endocrinology, hormone insight, GLP-1 weight loss, obesity pharmacotherapy

This week on Hormone Insight: the fallout from the ADA 2026 Scientific Sessions, where retatrutide — a triple GIP/GLP-1/glucagon agonist — delivered nearly 2 points of A1C and about 15% weight loss in type 2 diabetes (TRANSCEND-T2D-1). Plus CagriSema vs semaglutide head-to-head, finerenone in chronic kidney disease without diabetes, the new ADA/EASD type 1 diabetes consensus, and a Hormone Classic revisit of SUSTAIN-6 — the outcome bar every new drug still has to clear.

Segments:

• Trial of the Week — Retatrutide in type 2 diabetes (TRANSCEND-T2D-1, The Lancet)

• Quick Hit 1 — CagriSema vs semaglutide (REIMAGINE 2, Lancet Diabetes & Endocrinology)

• Quick Hit 2 — Finerenone in CKD without diabetes (FIND-CKD, NEJM)

• Guideline & FDA Watch — ADA/EASD type 1 diabetes in adults: 2026 consensus update

• Hormone Classic — SUSTAIN-6 (semaglutide cardiovascular outcomes, 2016)

⏱ Chapters

00:00 Cold open

00:38 Welcome & disclaimer

01:02 This week

01:47 Trial of the Week — Retatrutide (TRANSCEND-T2D-1)

03:51 The Appraisal

04:59 Bottom line — retatrutide

05:29 Quick Hit 1 — CagriSema vs semaglutide

06:54 Quick Hit 2 — Finerenone in CKD without diabetes

08:04 Guideline & FDA Watch — ADA/EASD type 1 diabetes

09:20 Hormone Classic — SUSTAIN-6

10:40 The Bottom Line

11:23 Sign-off

References & written summary: hormoneinsight.com/twide-2026-06-27

For healthcare professionals. Educational, not individual medical advice.

Subscribe for a new episode every Saturday. #diabetes #endocrinology #GLP1